ReviewExpert review of medical devices2025
An overview of utilizing artificial intelligence in localized prostate cancer imaging.
Review in Expert review of medical devices, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimizing clinical risk stratification of localized prostate cancer.Current opinion in urology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionProstate cancer (PCa) is a leading cause of cancer-related deaths among men, and accurate diagnosis is critical for effective management. Multiparametric MRI (mpMRI) has become an essential tool in PCa diagnosis due to its superior spatial resolution which enables detailed anatomical, functional information and its resultant ability to detect clinically significant PCa. However, challenges such as subjective interpretation methods and high inter-reader variability remain. In recent years, artificial intelligence (AI) has emerged as a promising solution to enhance the diagnostic performance of mpMRI by automating key tasks such as prostate segmentation, lesion detection, classification. AREAS COVERED: This review provides a comprehensive overview of the current AI applications in prostate mpMRI, discussing advancements in automated image analysis and how AI-driven models are developed to improve detection and risk stratification. A literature search was conducted to examine both machine learning and deep learning techniques applied in this field, highlighting key studies and future directions. EXPERT OPINION: While AI models have shown significant promise, their clinical integration remains limited due to the need for larger, multi-institutional validation studies. As AI continues to evolve, multimodal approaches combining imaging with clinical data are likely to play pivotal role in personalized PCa diagnosis, treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.